NCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
481 trialsNCT06510309 2026-03-13
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06510361 2026-03-13
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT07030699 2026-03-06
ECLAT
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05800366 2026-03-05
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06416085 2026-03-05
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT06698003 2026-03-05
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02974647 2026-02-27
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06563596 2026-02-19
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03316573 2026-02-10
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Phase 2 Suspended
NCT01511562 2026-01-30
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03943901 2026-01-29
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT01446133 2026-01-27
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06563505 2026-01-21
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07356245 2026-01-21
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT00364286 2026-01-20
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01352520 2026-01-20
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05464719 2026-01-12
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05929612 2026-01-09
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02106988 2026-01-07
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02490891 2026-01-02
RGDLymphome
Centre Henri Becquerel
Phase 2 Completed
NCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07062627 2025-12-17
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Asan Medical Center
Phase 2 Recruiting
NCT06218602 2025-12-16
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07285590 2025-12-16
IMCL-2023
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT05410418 2025-12-15
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05977673 2025-12-08
FIL_Tisle-HL
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT05991973 2025-12-05
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Zhejiang University
Phase 2 Completed
NCT06986174 2025-12-05
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07014319 2025-12-04
MALMBA
Seoul National University Hospital
Phase 2 Recruiting
NCT05099471 2025-11-28
VIWA-1
University of Ulm
Phase 2 Recruiting
NCT07254754 2025-11-28
LATE-R-GEL-23
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT02588651 2025-11-21
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03747757 2025-11-10
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02323867 2025-10-31
AB-CliniMACs
Children's Hospital of Philadelphia
Phase 2 Active not recruiting
NCT03856216 2025-10-16
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT07206264 2025-10-03
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT01258933 2025-10-01
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06439420 2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2 Completed
NCT00690560 2025-09-30
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Centre Antoine Lacassagne
Phase 2 Completed
NCT04083495 2025-09-22
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT04975555 2025-09-22
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT00498043 2025-09-03
LNH2007-3B
Hospices Civils de Lyon
Phase 2 Completed
NCT01810588 2025-09-02
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT07126236 2025-08-17
REPIFIR
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT07094477 2025-07-30
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Chinese PLA General Hospital
Phase 2 Active not recruiting
NCT03862131 2025-07-29
PROACT
Washington University School of Medicine
Phase 2 Terminated